Tarasov
Aleksey Zaharovich Tarasov, Moscow RU
Patent application number | Description | Published |
---|---|---|
20140145027 | AIRCRAFT WITH AN INTEGRAL AERODYNAMIC CONFIGURATION - The invention relates to multimode aircraft operated at supersonic and subsonic flight speeds in a wide range of flight altitudes. The invention is particularly applicable in multimode super-maneuverable aircraft capable of cruising at supersonic speed and having low radar signature. The technical effect to be achieved by the invention is to provide an aircraft which has low radar signature, is super-maneuverable at high angles of attack, has high aerodynamic efficiency at supersonic speeds while keeping high aerodynamic efficiency at subsonic modes, and can accommodate bulky cargo in its internal compartments. The integral aerodynamic configuration aircraft comprises fuselage ( | 05-29-2014 |
Alexander Tarasov, Limerick IE
Patent application number | Description | Published |
---|---|---|
20100077378 | Virtualised Application Libraries - The present invention provides a method and system for virtualizing a code library. The method comprises providing a description of at least one function in said code library. The description includes properties of any parameter and of any data structure required by said function. Code for a stub library for a client computer from which a library function may be called remotely is then generated. The stub library is operable to construct, in accordance with said description, a transportable data message for calling a function of said code library, the construction including determining properties of any parameter required by said called function and obtaining the argument value referred to by any pass-by-reference parameter. Code for a skeleton library, for a host computer on which said code library is hosted, is also generated. The skeleton library is operable to invoke execution of said called function in response to receipt of said transportable data message. The stub library exactly mimics the interface of the local client libraries, allowing remote functions to be called directly without using any specific API calls. This provides simple and fast remote procedure call enablement of applications with minimum programming effort, allowing applications to benefit from the direct calling of functions on remote computers. | 03-25-2010 |
Alexander Vladimirovich Tarasov, Odintsovsky R-N RU
Patent application number | Description | Published |
---|---|---|
20130189707 | METHOD OF DETERMINATION OF AUTOANTIBODY LEVEL BY MEANS OF ENZYME IMMUNOASSAY - The method for quantitative determination of the level of natural autoantibodies in human biological fluids, when as a solid phase of physical sorption is used the solid phase of physical sorption, coated with streptavidin, and the solid phase of physical sorption is treated with preliminary biotinylated antigen and blocking agent for closing the sites of nonspecific binding at the solid phase of physical sorption, for which purpose are used proteins, biotinylated according to standard procedure. As the conjugate-containing solution are used enzyme-labeled monoclonal and polyclonal antibodies, which react with one or all isotypes of human immunoglobulins. In addition, the tested biological fluid is preliminary diluted in a buffer, containing proteins which are used for closing the sites of nonspecific binding at solid phase of physical sorption, and also substances protecting natural autoantibodies from destruction during heat treatment, and subjected to heat treatment. For each tested specimen of biological fluid, a control solid phase of physical sorption is used, and the number of natural autoantibodies is determined with the use of a calibration curve which is plotted using monoclonal or polyclonal antibodies to antigen. | 07-25-2013 |
Alexandr Andreevich Tarasov, Kiev UA
Patent application number | Description | Published |
---|---|---|
20110064818 | PHARMACEUTICAL COMPOSITION AND A METHOD FOR THE PRODUCTION THEREOF - The invention relates to producing medicinal agents for treating diabetes. There is proposed a method for producing a pharmaceutical composition containing insulin on a polysaccharide carrier, which involves mixing initial ingredients, wherein there is provided, for mixing, supplying positively charged chitosan sol with pH of 3.5 to 4.5 and negatively charged zinc free insulin, which is taken in the form of a colloidal solution or in the form of nanosized crystalline particles, bringing the pH of the mixed sol to a value of 5.5 to 6.5, producing a gel and dehydrating the produced gel to obtain solid particles, the size of which ranges from 10 to 100 mkm. The method makes it possible to produce a stable controlled release insulin-containing composition for peroral administration | 03-17-2011 |
Boris Tarasov, Sorrento AU
Patent application number | Description | Published |
---|---|---|
20100090435 | Arm and Leg Powered Vehicle - An arm and leg powered vehicle includes a chassis mounted on a plurality of wheels, at least one of said wheels being a drive wheel wherein rotation of the drive wheel propels the vehicle forward, a seat mounted on the chassis for a rider to sit on, the seat being constrained against longitudinal movement relative to the chassis, a handlebar operatively connected to a steering rod whereby axial rotation of the handlebar generates a turn on at least one of said wheels, the handlebar including a handle holder arranged to move in a linear reciprocating manner relative to the steering rod, a foot pedal housing arranged to move in a linear reciprocating manner relative to a rail fixedly connected to the chassis, and, a power transmission system for receiving power from the arms of the rider in response to the application of a pulling force to the handlebar and from the legs of the rider in response to the application of the pushing force to the foot pedal housing and for transmission of the received power to the drive wheel. When the arms and legs of the rider are used independently, the power transmission system is configured to receive and transmit power from the arms or the legs of the rider, and when the arms and legs of the rider are used simultaneously, the power transmission system is configured to receive and transmit the sum of the power from the arms and the legs of the rider. | 04-15-2010 |
Dmitry Nikolaevich Tarasov, Moskovskaya Oblast RU
Patent application number | Description | Published |
---|---|---|
20100112724 | METHOD OF DETERMINATION OF PROTEIN LIGAND BINDING AND OF THE MOST PROBABLE LIGAND POSE IN PROTEIN BINDING SITE - The present invention proposes a method of structural design, search and selection of potential medicinal compounds—ligands, comprising prognostication of the value of the protein ligand binding in terms of the score calculated with the help of the scoring function developed for scoring, and prognostication of the most probable ligand pose in the protein binding site in terms of the score calculated with the help of the scoring function developed for docking (the docking function). It is proposed to use two absolutely different scoring functions for docking and scoring. A special procedure is proposed for the development of docking function. Use of two absolutely different functions in the process of docking and scoring principally distinguishes the proposed method of predicting the binding affinity of ligand-protein interaction from all the known methods and makes it possible to substantially improve the quality of said prediction. | 05-06-2010 |
Dmitry Nikolaevich Tarasov, Moskovskaya Obi. RU
Patent application number | Description | Published |
---|---|---|
20130005778 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA - The invention relates to a new class of compounds, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions that are effective as selective inhibitors of factor Xa, both in the isolated state and in a complex with other proteins. The compounds of the invention can be used for treating and preventing diseases, such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, thromboses caused by post-thrombolytic therapy or coronary angioplasty, acute ischemia mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, and other diseases in humans and other mammals associated with blood coagulation problems. | 01-03-2013 |
Kirill Tarasov, Espoo FI
Patent application number | Description | Published |
---|---|---|
20120258123 | BIOMARKERS FOR SENSITIVE DETECTION OF STATIN-INDUCED MUSCLE TOXICITY - The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity. | 10-11-2012 |
20130045217 | LIPIDOMIC BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE - The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD. | 02-21-2013 |
20130216560 | Lipidomic Biomarkers for Identification of High-Risk Coronary Artery Disease Patients - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 08-22-2013 |
20140031332 | Biomarkers for Sensitive Detection of Statin-Induced Muscle Toxicity - The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity. | 01-30-2014 |
20140295466 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 10-02-2014 |
20140295467 | LIPIDOMIC BIOMARKERS FOR THE PREDICTION OF CARDIOVASCULAR OUTCOMES IN CORONARY ARTERY DISEASE PATIENTS NOT UNDERGOING STATIN TREATMENT - The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications. | 10-02-2014 |
Sergei Alexandrovich Tarasov, Golitsyno RU
Patent application number | Description | Published |
---|---|---|
20130224219 | DRUG AND METHOD FOR THE PROPHYLAXIS OF HIV INFECTION AND FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES CAUSED BY OR ASSOCIATED WITH HIV, INCLUDING AIDS - The drug for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, comprises an activated, potentiated form of antibodies to a protein or peptide of the immune system which interacts with the HIV or has a content and/or functional activity which changes in connection with an HIV infection. Furthermore, in the method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including AIDS, use is made of an activated, potentiated form of antibodies to an antigen, namely a protein or peptide of the immune system, which interacts with the HIV or has a content and/or functional activity which changes in connection with an HIV infection | 08-29-2013 |
Sergei Alexandrovich Tarasov, Odintsovsky R-N RU
Patent application number | Description | Published |
---|---|---|
20130189707 | METHOD OF DETERMINATION OF AUTOANTIBODY LEVEL BY MEANS OF ENZYME IMMUNOASSAY - The method for quantitative determination of the level of natural autoantibodies in human biological fluids, when as a solid phase of physical sorption is used the solid phase of physical sorption, coated with streptavidin, and the solid phase of physical sorption is treated with preliminary biotinylated antigen and blocking agent for closing the sites of nonspecific binding at the solid phase of physical sorption, for which purpose are used proteins, biotinylated according to standard procedure. As the conjugate-containing solution are used enzyme-labeled monoclonal and polyclonal antibodies, which react with one or all isotypes of human immunoglobulins. In addition, the tested biological fluid is preliminary diluted in a buffer, containing proteins which are used for closing the sites of nonspecific binding at solid phase of physical sorption, and also substances protecting natural autoantibodies from destruction during heat treatment, and subjected to heat treatment. For each tested specimen of biological fluid, a control solid phase of physical sorption is used, and the number of natural autoantibodies is determined with the use of a calibration curve which is plotted using monoclonal or polyclonal antibodies to antigen. | 07-25-2013 |
Sergey Alexandrovich Tarasov, Golitsyno RU
Patent application number | Description | Published |
---|---|---|
20120263725 | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS. | 10-18-2012 |
20120263726 | Pharmaceutical composition and method of inhibiting of production or amplifying of elimination of P24 protein - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of inhibiting of production or amplifying of elimination of P24 protein. | 10-18-2012 |
20120294899 | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to HIV protein, and method of treating and preventing the diseases caused by HIV or associated with HIV, including AIDS. | 11-22-2012 |
20130017202 | Pharmaceutical compositions and methods of treatmentAANM Epshtein; Oleg IliichAACI MoscowAACO RUAAGP Epshtein; Oleg Iliich Moscow RUAANM Sergeeva; Svetlana AlexandrovnaAACI MoscowAACO RUAAGP Sergeeva; Svetlana Alexandrovna Moscow RUAANM Dolgovyh; Liudmila FyodorovnaAACI ChelyabinskAACO RUAAGP Dolgovyh; Liudmila Fyodorovna Chelyabinsk RUAANM Kheyfets; Irina AnatolievnaAACI DolgoprudnyAACO RUAAGP Kheyfets; Irina Anatolievna Dolgoprudny RUAANM Dugina; Julia LeonidovnaAACI MoscowAACO RUAAGP Dugina; Julia Leonidovna Moscow RUAANM Zabolotneva; Julia AlexandrovnaAACI MoscowAACO RUAAGP Zabolotneva; Julia Alexandrovna Moscow RUAANM Tarasov; Sergey AlexandrovichAACI GolitsynoAACO RUAAGP Tarasov; Sergey Alexandrovich Golitsyno RU - The present invention provides pharmaceutical compositions comprising an activated potentiated form of an antibody to human cannabinoid receptor and use in the treatment of obesity and related metabolic disorders. The present invention further provides pharmaceutical compositions comprising an activated potentiated form of an antibody to human cannabinoid receptor and activated potentiated form of an antibody to protein S-100 for use in the treatment of addiction to psychoactive substances. | 01-17-2013 |
20130315964 | PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITING OF PRODUCTION OR AMPLIFYING OF ELIMINATION OF P24 PROTEIN - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of inhibiting of production or amplifying of elimination of P24 protein. | 11-28-2013 |
20150023972 | COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES - The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS. | 01-22-2015 |
20150023980 | COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES - The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS. | 01-22-2015 |
Sergey Alexandrovish Tarasov, Golitsyno RU
Patent application number | Description | Published |
---|---|---|
20130045237 | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases - The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different infectious agents such as pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, and acute and chronic viral infections such as acute respiratory tract infections, influenza of different types, acute viral hepatitis A, B, C and other types of hepatitis, the diseases and conditions caused by HIV or associated with HIV, including AIDS. | 02-21-2013 |
Sergey G. Tarasov, Frederick, MD US
Patent application number | Description | Published |
---|---|---|
20100034896 | SELF-ASSEMBLING NANOPARTICLES COMPOSED OF TRANSMEMBRANE PEPTIDES AND THEIR APPLICATION FOR SPECIFIC INTRA-TUMOR DELIVERY OF ANTI-CANCER DRUGS - The invention provides a method of handling a hydrophobic agent, which method comprises (a) combining in an aqueous solution (i) a hydrophobic agent and (ii) an isolated peptide that is a structural analog of a transmembrane domain of an integral membrane protein, wherein one terminus of the peptide has one or more negatively charged residues, and (b) allowing the peptide to self-assemble into nanoparticles, wherein the nanoparticles comprise the hydrophobic agent. | 02-11-2010 |
20100184697 | PEPTIDE-BASED STAT INHIBITOR - A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods. | 07-22-2010 |
20110195911 | SYNTHETIC ANALOGS OF THE JUXTAMEMBRANE DOMAIN OF IGF1R AND USES THEREOF - A peptide or peptidomimetic comprising the amino acid sequence RXGNGV (SEQ ID NO: 1) or the inverse thereof, or comprising at least six contiguous amino acids of the juxtamembrane domain of IGF1R (SEQ ID NO: 43) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50 or fewer amino acids and inhibits IFG-R1 activity, as well as a method of inhibiting a IGF1R in a cell, a method of treating or preventing IGF1R-mediated disease, and related compounds, compositions, and methods. | 08-11-2011 |
20140135276 | LIPOPEPTIDE INHIBITORS OF RAS ONCOPROTEINS - The invention provides a peptide or peptidomimetic that is derived from or based upon the amino acid sequence of the C-terminal α-helix or hypervariable region (HVR) or a Ras protein, a nucleic acid encoding the peptide or peptidomimetic, and methods employing the same. | 05-15-2014 |
Sergey Vladimirovich Tarasov, Saratov RU
Patent application number | Description | Published |
---|---|---|
20090040689 | ELECTRODE AND CURRENT COLLECTOR FOR ELECTROCHEMICAL CAPACITOR HAVING DOUBLE ELECTRIC LAYER AND DOUBLE ELECTRIC LAYER ELECTROCHEMICAL CAPACITOR FORMED THEREWITH - An electrode and a DEL capacitor formed therewith. The electrode will typically be a polarizable electrode, and may be formed of an activated carbon material having a substantially zero ash percentage and a low percentage of transition metals. In constructing a DEL capacitor employing such an electrode, a non-polarizable electrode formed from a lead dioxide/lead sulfate compound is preferably also used. The DEL capacitor may utilize an acid-based electrolyte, such as an aqueous sulfuric acid electrolyte. Consequently, the present invention also includes a current collector that preferably comprises a base material formed from a lead or a lead compound and a protective coating material that is resistant to an acid-based electrolyte. Preferably, the protective coating material is formed from a polymer base and a conductive dope that may thereafter be applied to the current collector base material by a variety of methods. | 02-12-2009 |
20130300019 | METHOD OF MANUFACTURING POLARIZABLE ELECTRODES FOR USE IN ELECTROCHEMICAL CAPACITORS - A method of manufacturing polarizable electrode plates for use in an electrochemical capacitor having a high energy storage capacity. The plates are made of a dry activated carbon and modifying agent mixture combined with a binder. The plates are manufactured by mixing and grinding the mixture, combining the mixture with the binder to form a paste, removing free water from the paste, forming work pieces of desired dimensions from the paste, drying the work pieces, and then forming electrode plates from the work pieces by rolling without the use of processing liquids. | 11-14-2013 |
Vasily Tarasov, Stony Brook, NY US
Patent application number | Description | Published |
---|---|---|
20110029946 | EFFICIENT EXTRACTION OF SOFTWARE DEPENDENCIES FROM PROGRAM CODE - Calls to stop functions are identified in a computer program file. The stop functions are functions that interact with external resources. Parameters of the calls to the stop functions that are references to the external resources are identified. An analysis is performed over the computer program file to find out possible values of the parameters of the calls. | 02-03-2011 |
20120278295 | DISK IMAGE INTROSPECTION FOR STORAGE SYSTEMS - A method for disk image access in a storage system comprises receiving an input/output (I/O) request to a disk image in a file system of a storage system, and in response to the I/O request to the disk image in the file system, reconstructing a file system request. Introspection is performed on the disk image to determine an original file system request based on the I/O request to the disk image. The method further includes laying out a disk image in the file system of the storage system, and performing type-specific introspection on the disk image. Based upon the results of the introspection, data ranges in the disk image are mapped to block or files within the file system. A mapping of disk image data ranges to block or files in the file system is maintained for responding to further I/O requests. | 11-01-2012 |
20130290937 | EFFICIENT EXTRACTION OF SOFTWARE DEPENDENCIES FROM PROGRAM CODE - Calls to stop functions are identified in a computer program file. The stop functions are functions that interact with external resources. Parameters of the calls to the stop functions that are references to the external resources are identified. An analysis is performed over the computer program file to find out possible values of the parameters of the calls. | 10-31-2013 |
Vasily Tarasov, Hawthorne, NY US
Patent application number | Description | Published |
---|---|---|
20110055806 | METHOD AND SYSTEM TO DISCOVER POSSIBLE PROGRAM VARIABLE VALUES BY CONNECTING PROGRAM VALUE EXTRACTION WITH EXTERNAL DATA SOURCES - A system and method of discovering one or more program variable values may extract an abstract interpretation of a program variable used in a computer program, locate installation-specific repositories associated with the computer program, parse the located installation-specific repositories and extract one or more configuration parameters, and substitute the one or more configuration parameters into the extracted abstract interpretation. | 03-03-2011 |
Vladimir Tarasov, Frederick, MD US
Patent application number | Description | Published |
---|---|---|
20090260935 | REGENERATIVE SHOCK ABSORBER - Regenerative shock absorber. A piston is disposed for reciprocating motion within a cylinder as a vehicle's suspension system deflects. Hydraulic fluid passes through an hydraulic motor to turn its shaft. The hydraulic motor shaft is connected to an electric generator to generate electricity. Flow characteristics of hydraulic circuits are selected to provide suspension system damping for appropriate wheel control. | 10-22-2009 |
Vladimir S. Tarasov, Somerville, MA US
Patent application number | Description | Published |
---|---|---|
20140255615 | Apparatus and Process for Depositing a Thin Layer of Resist on a Substrate - The present inventions relate to the formation of a thin polymer film on a substrate. Apparatus is described for transforming a solid polymer resist into an aerosol of small particles, electrostatically charging and depositing the particles onto a substrate, and flowing the particles into a continuous layer. Apparatus is further described for transforming solid resist into an aerosol of small particles by heating the resist to form a low viscosity liquid such as is compatible with nebulization and applying the techniques of jet or impact nebulization and aerosol particle sizing to form the aerosol. A method is further described of using ionized gas to confer charge onto the aerosol particles and using a progression of charging devices establish an electric field directing the flow of charged particles to the substrate. The progression of charging devices and associated apparatus results in high collection efficiency for the aerosol particles. | 09-11-2014 |
20150037923 | METHODS TO SELECTIVELY TREAT PORTIONS OF A SURFACE USING A SELF-REGISTERING MASK - Processes increase light absorption into silicon wafers by selectively changing the reflective properties of the bottom portions of light trapping cavity features. Modification of light trapping features includes: deepening the bottom portion, increasing the curvature of the bottom portion, and roughening the bottom portion, all accomplished through etching. Modification may also be by the selective addition of material at the bottom of cavity features. Different types of features in the same wafers may be treated differently. Some may receive a treatment that improves light trapping while another is deliberately excluded from such treatment. Some may be deepened, some roughened, some both. No alignment is needed to achieve this selectively. The masking step achieves self-alignment to previously created light trapping features due to softening and deformation in place. | 02-05-2015 |
Yuriy Tarasov, Santa Clara, CA US
Patent application number | Description | Published |
---|---|---|
20150033275 | CONTROLLING DEVICES IN ENTERTAINMENT ENVIRONMENT - Embodiments for controlling one or more external audio-visual devices are provided. In one example, a method comprises receiving a device command and determining an intent of the device command. The intent includes an action and an external device to perform the action. The method further comprises selecting a selected protocol for communicating the device command to the external device, where the selected protocol is selected from a plurality of supported protocols, and communicating the device command to the external device according to the selected protocol. | 01-29-2015 |